Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
that the European Patent Office granted a key patent covering label-relevant dosing regimens for its lead asset, vidofludimus calcium. The patent is expected to protect Europe through 2038 and may be eligible for a Supplementary Protection Certificate, which could extend exclusivity to as late as 2043. Immunic, Inc. (NASDAQ:IMUX) noted that the claims broadly cover vidofludimus and its salt, solvate, and free acid forms across all label-relevant dosing regimens, meaning protection is not limited to a single formulation and may extend to alternative forms used according to the approved label. The patent had previously been granted in the United States in 2023. Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium Copyright: zneb076 / 123RF Stock Photo On March 2, 2026, H.C. Wainwright lowered its price target on Immunic, Inc. (NASDAQ:IMUX) to $5 from $8 previously and maintained a Buy rating after updating its model. Immunic, Inc. (NASDAQ:IMUX) develop
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]Yahoo! Finance
- Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPR Newswire
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Analyst Actions
- 2/9/26 - HC Wainwright
IMUX
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form D
- 3/2/26 - Form DEF
- IMUX's page on the SEC website